AIxplorerBio Entered A Broad Collaboration with Baidu's PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R&D Platform

Source:AIxplorerBio Time:2022-05-18

On May 18, AIxplorerBio announced a broad collaboration with PaddleHelix. The two parties will leverage their strengths and collaborate in the fields of de novo molecular design and druggability evaluation, to accelerate new AI-powered drug research and development platform. The collaboration takes fully advantage of PaddleHelix's strengths in AI technologies and AIxplorerBio's experience in new drug RD and experiemental capabilities to jointly develop AI-powered drug discovery models. Dr. David. Xu, CEO of AIxplorerBio, emphasized, "AIxplorerBio is an AI-powered, structure-based drug R&D biotech company. The collaboration with Baidu's PaddleHelix will help enhance our new AI drug RD platform - AIxMolTM, and speed up the development of our pipeline."